Q2 Breathes A Little Life Into Medtech IPO Scene
Executive Summary
After a lackluster first quarter, the medtech IPO scene is gradually livening up with several companies their shares successfully floated on the public markets for the first time in the second quarter. But activity levels are still a far cry from the bonanza of 2015.
You may also be interested in...
Oncimmune Hits IPO Target
Early cancer detection specialist Oncimmune has joined AIM, the London Stock Exchange’s international market for emerging companies, after successfully completing its initial public offering and raising £11m ($15.7m) in gross proceeds. The company’s market capitalization on admission to AIM is around £66.3m; it is trading under the symbol “ONC.L”.
Medtech IPO Environment Cools With Sluggish Q1
If the first quarter’s IPO activity levels are anything to go by, it looks like medtech companies may be facing a cooler public fundraising climate in 2016.
IPO ROUND-UP: Public appetite for medtech stocks on the up
With June proving to be a bumper month for completed IPOs, the first half of 2015 looks well on its way to outperform 2014 when it comes to stock float successes.